Clinical trial · Observational
Musculoskeletal Health in Adult Haematological Cancer Survivors
Musculoskeletal Health in Adult Haematoloigcal Cancer Survivors - a Mixed Methods Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Haematological cancer treatment often includes use of high dose glucocorticoids (steroids), chemotherapy and radiotherapy and current evidence suggests that these patients may have lower bone mineral density after treatment when compared to the general population which can predispose them to increased risk of fragility fractures. Evidence of the impact of these musculoskeletal burden to patients (e.g. quality of life) are not available. This study aims to describe musculoskeletal complications experienced by long-term haematological cancer survivors and examine the impact of the burden from the patient perspective. The study will be conducted in 2 parts; a questionnaire study and an interview study to help understand the extent of musculoskeletal problems experienced by this group of patients and the impact of this on quality of life.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Not an intervention study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (32)
- label
- 5-10 years post cancer treatment; male; age at diagnosis 18-30
- interventionNames
- Other: Not an intervention study
- label
- 5-10 years post cancer treatment; male; age at diagnosis 31-50
- interventionNames
- Other: Not an intervention study
- label
- 5-10 years post cancer treatment; male; age at diagnosis 51-70
- interventionNames
- Other: Not an intervention study
- label
- 5-10 years post cancer treatment; male; age at diagnosis 70+
- interventionNames
- Other: Not an intervention study
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Questionnaire study Inclusion Criteria: 1. Age 18 or above at diagnosis of haematological cancer 2. Diagnosis of haematological cancers: lymphoma or leukaemia 3. Cancer survivors as recorded in the local database of lymphoma and haematopoietic stem cell transplant database 4. Able to give written informed consent 5. Able to read and understand English Exclusion Criteria: 1.Currently receiving any active cancer treatment Interview study Inclusion Criteria: 1. Age 18 or above at diagnosis of haematological cancer 2. Diagnosis of haematological cancers: lymphoma or leukaemia 3. Cancer survivors as recorded in the local database of lymphoma and haematopoietic stem cell transplant database 4. Able to give written or verbal informed consent 5. Able to read and understand English Exclusion Criteria: 1 .Currently receiving any active cancer treatment
References
Publications (0)
Data not yet available